Trends of Antifungal Agent Susceptibility of Candida Strains Isolated from Blood Cultures in 2009~2018

• Published in: Korean Journal of Clinical Laboratory Science Vol. 54; no. 2; pp. 133 - 141
• Main Authors: Hwang, Yu-Yean, Kang, On-Kyun, Park, Chang-Eun, Lee, Moo-Sik, Kim, Young-Kwon, Huh, Hee-Jae, Lee, Nam-Yong
• Format: Journal Article
• Language: English
• Published: The Korean Society for Clinical Laboratory Science 30-06-2022
• Subjects: antifungal agent susceptibility; blood culture; candida bloodstream infections; candida species; candidemia
• ISSN: 1738-3544; 2288-1662
• DOI: 10.15324/kjcls.2022.54.2.133

Candida is one of the most common causes of bloodstream infections and a leading cause of morbidity and mortality among hospitalized patients. The purpose of this study was to provide important information for formulating empirical treatment plans for candidemia by investigating the antifungal resistance rate of Candida. Among the Candida strains (973 cases) isolated from blood culture tests at the S hospital in 2009~2018, 4.7% (N=44) comprising the Candida spp. (932 strains) showed resistance to fluconazole. The resistant strains included C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata. In addition Candida spp. (947 strains) showed resistance to amphotericin B (N=6, 0.6%), flucytosine (N=23, 2.4%) and voriconazole (N=24, 3.1%). C. albicans was resistant to fluconazole (N=23, 6.9%) and voriconazole (N=21, 6.0%), The statistical analysis showed that C. albicans and non-albicans Candida species were resistant to fluconazole (P=0.039) and voriconazole (P<0.001). A monitoring system to understand the rate of candidiasis infections in a hospital setting is required. It is also important to make the right choice of the antifungal agent based on drug susceptibility patterns. Therefore, an infection surveillance policy that tracks Candida resistance through regular antifungal susceptibility tests is necessary.